MANFMesencephalic Astrocyte-Derived Neurotrophic Factor (protein type)
MANFMake a Noise Foundation (Nashville, TN)
References in periodicals archive ?
RBCC and Amarantus are currently wrapping up due diligence toward a potential joint venture agreement to develop and market MANF as a treatment for disorders associated with endoplasmic reticulum stress, including traumatic brain injury, Parkinson's disease, Alzheimer's disease and other afflictions.
Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates.
While Amarantus will continue to focus our internal MANF development efforts on protein therapeutics, we believe strongly in the additional potential of MANF if developed as a gene therapy, and look forward to engaging potential partners with a successful track record in this exciting field".
MANF is released from glial cells in the midbrain and is a member of the same growth factor family as CDNF.
The Opposition Division held that Hermo Phrama's arguments did not prejudice the maintenance of the patent as originally granted, with broad claims covering MANF and its derivatives.
While Parkinson's disease and traumatic brain injury are both afflictions suffered by large populations of patients worldwide, Amarantus' research indicates that MANF may also be well-suited to treating many rare and ultra-rare neurological ailments, as well.
This study generated MANF brain delivery and distribution data, further supporting the rationale for MANF's development in the treatment of Parkinson's disease (PD).
The ability to advance NuroPro that will simultaneously generate revenue while bolstering our MANF program by allowing our clinical researchers to more efficiently select and monitor Parkinson's patients in our therapeutic program represents a tremendous opportunity.
OTC: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, today announced that it has entered into a manufacturing agreement with Catalent Pharma Solutions (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, for clinical-grade production of MANF (mesencephalic-astrocyte-derived neurotrophic factor).
This transaction will allow Amarantus to gain upside from the licensing of the NuroPro asset, while defraying the costs of the project in order to focus our internal resources on the MANF Program for Parkinson's disease and Traumatic Brain Injury.
OTCQB: AMBS), a biotechnology company focused on developing therapeutic and diagnostic products for neurological disorders and orphan indications, announced that the European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has granted orphan drug status for MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of retinitis pigmentosa (RP).
Amarantus owns the rights to a promising therapeutic protein known as MANF that prevents a type of cell death called apoptosis that could be the beginning of a cure for the disease.